Clinical Trials Sponsored by ALL-BFM Study Group

Total 62 results

St. Anna Kinderkrebsforschung
International BFM Study Group

Unknown

Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia

Lymphoblastic Leukemia, Acute, Childhood;

Austria, Germany
German CLL Study Group

Active, not recruiting

Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

Richter Transformation

Denmark, Germany, Austria
German CLL Study Group

Completed

Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Completed

Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Prolymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Active, not recruiting

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG)

Chronic Lymphoid Leukemia

Germany
German CLL Study Group

Active, not recruiting

Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail)

Chronic Lymphoid Leukemia

Austria, Germany
German CLL Study Group

Completed

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL (CLL2-BAAG)

Chronic Lymphoid Leukemia

Germany
Czech CLL Study Group

Completed

Observational Study in CLL Patients Receiving BR

Chronic Lymphocytic Leukemia

Czechia
German CLL Study Group

Completed

Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Completed

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Recruiting

Registry of the German CLL Study Group (CLL-Registry)

CLL | Leukemia, Prolymphocytic, T-Cell | SLL | Leukemia, Prolymphocytic, B-Cell | HCL | T-LGL Leukemia | Richter´s Transformation | NK-LGL Leukemia

Germany
German CLL Study Group

Completed

Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

France, Germany, Austria
German CLL Study Group

Completed

Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia

Anemia | Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Completed

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia

Canada, Germany
German CLL Study Group

Terminated

Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia

T-Cell Large Granular Lymphocytic Leukemia

Germany
German CLL Study Group

Terminated

Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
German CLL Study Group

Terminated

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia

Prolymphocytic Leukemia

Germany
Czech CLL Study Group

Unknown

Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project (Q-lite)

Chronic Lymphocytic Leukemia

Czech Republic
German CLL Study Group
AstraZeneca

Recruiting

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group
Celgene

Completed

A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

Chronic Lymphocytic Leukemia

Germany
Children's Oncology Group
National Cancer Institute (NCI); EsPhALL Network/ BFM Study Group

Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel
Stichting Hemato-Oncologie voor Volwassenen Nederland
German CLL Study Group; Nordic CLL Study Group

Recruiting

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (AETHER)

CLL/SLL

Netherlands, Denmark, Belgium, Germany
Gilead Sciences
German CLL Study Group

Completed

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Gilead Sciences
German CLL Study Group

Completed

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Dutch Childhood Oncology Group
St. Jude Children's Research Hospital; International BFM Study Group

Completed

Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
German CLL Study Group
Janssen-Cilag Ltd.

Completed

Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression (CLL12)

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group
University of Cologne

Completed

Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
Hoffmann-La Roche
German CLL Study Group

Completed

Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia (CLL-8)

Leukemia

France, Australia, Belgium, Italy, Germany, Israel, New Zealand, Czech Republic, Spain, Austria, Denmark
German CLL Study Group
Hoffmann-La Roche

Terminated

Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation (CLLTX1)

Chronic Lymphocytic Leukemia | Richter's Transformation

Germany
Munich Municipal Hospital
German CLL Study Group

Unknown

CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients

Chronic Lymphocytic Leucemia

Germany
Rabin Medical Center
International BFM Study Group; Israeli Society for Pediatric Hematology-Oncology

Recruiting

Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia

Lymphoma | Leukemia | Ataxia Telangiectasia

Israel
German CLL Study Group
AbbVie; Hoffmann-La Roche

Active, not recruiting

Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

Chronic Lymphocytic Leucemia

Germany
Hoffmann-La Roche
AbbVie; German CLL Study Group

Active, not recruiting

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

United States, Spain, France, United Kingdom, Australia, Canada, Denmark, Germany, Italy, Brazil, Argentina, Estonia, New Zealand, Austria, Bulgaria, Croatia, Romania, Russian Federation, Poland, Switzerland, Mexico
German CLL Study Group
Gilead Sciences; Novartis Pharmaceuticals

Completed

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Completed

Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine

Leukemia

Germany, Austria
Rabin Medical Center
International BFM Study Group; Israeli Society for Pediatric Hematology-Oncology

Recruiting

Lymphoproliferative Disorders After Diagnosis of Childhood Acute Lymphoblastic Leukemia/Lymphoma

Childhood Leukemia and Lymphoma

Israel
St. Anna Kinderkrebsforschung
Assistance Publique - Hôpitaux de Paris; Australian & New Zealand Children's... and other collaborators

Recruiting

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukaemia

Italy, Israel, Spain, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, Croatia, Czechia, Denmark, Finland, Greece, Malaysia, Mexico, Netherlands, Norway, Poland, Romania, Saudi Arabia, Slovakia, Sweden, Switzerland, Turkey, F... and more
Hoffmann-La Roche
Genentech, Inc.; German CLL Study Group

Completed

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

Lymphocytic Leukemia, Chronic

Australia, France, Germany, Italy, Spain, Hong Kong, Canada, Switzerland, Estonia, Mexico, New Zealand, Denmark, Russian Federation, United States, Austria, Bulgaria, Czechia, United Kingdom, Thailand, Romania, Croatia, Brazil, Arge... and more
German CLL Study Group
Gilead Sciences; Hoffmann-La Roche

Completed

Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

Chronic Lymphocytic Leucemia

Germany
Hoffmann-La Roche
Genentech, Inc.; German CLL Study Group

Completed

CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)

Lymphocytic Leukemia, Chronic

Australia, France, Germany, Italy, Spain, Hong Kong, Canada, Switzerland, Estonia, Mexico, New Zealand, Denmark, Russian Federation, United States, Austria, Bulgaria, Czechia, United Kingdom, Thailand, Romania, Croatia, Brazil, Arge... and more
Hoffmann-La Roche
Genentech, Inc.; German CLL Study Group

Completed

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)

Lymphocytic Leukemia, Chronic

Australia, France, Germany, Spain, Hong Kong, Canada, Switzerland, Estonia, Mexico, New Zealand, Denmark, Russian Federation, United States, Austria, Bulgaria, Czechia, United Kingdom, Italy, Thailand, Romania, Croatia, Brazil, Arge... and more
German CLL Study Group
University of Cologne; MedacSchering Onkologie

Completed

Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)

B-cell Chronic Lymphocytic Leukemia

Germany
German CLL Study Group
AbbVie; Hoffmann-La Roche; Swiss Group for Clinical Cancer Research; Stichting... and other collaborators

Completed

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation (GAIA)

Chronic Lymphocytic Leukemia

Ireland, Germany, Israel, Austria, Belgium, Denmark, Switzerland, Finland, Sweden, Netherlands
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group

Active, not recruiting

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in Remission

Netherlands, Belgium, Denmark, Finland, Norway, Sweden
German CLL Study Group
Mundipharma Pte Ltd.; Roche Pharma AG

Completed

FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany

Clinical Trials Sponsored by ALL-BFM Study Group

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations